Select Page

Nanodrugs GMP Manufacturing

Our GMP facilities for Nanotechnology Enabled Products (NEP) are sized to successfully manufacture your product for clinical development and commercial supply.

GTP Bioways CDMO - Antibody drug conjugate development

GMP manufacturing of nanodrugs from clinic to market

With production capacities up to 60 kg, GTP Bioways is the ideal partner to cover your manufacturing needs during pre-clinical and clinical development of your nanodrug – and for commercialisation too when developing an orphan drug.

Our expertise covers the manufacturing in liquid form, including high viscous gel, of a wide range of molecules including highly potent compounds. We can deliver nanosuspensions, nanoemulsions, lipid and polymer nanoparticles as sterile finished drug products in vials or syringes.

We provide many options for the manufacturing of a sterile product: sterilising filtration, final sterilisation by autoclave and even full-aseptic manufacturing through fully adaptable and flexible tools. Whatever your needs and your process, we will be able to adapt to your constraints and requirements. Our manufacturing services are supported by a full package of analytical method development services and ICH stability programmes.


Our highly flexible equipments are built off hig-pressure homogenisation (HPH) technology. With this unique technology, we can manufacture your NEP up to a level of 60 kg in a 100% cGMP compliant environment.

Cell line Development process

cGMP manufacturing of cytotoxic nanodrugs

Because we are aware that many NEP may contain cytotoxic compounds, we have designed our facilities to be able to handle highly potent molecules.

We can manufacture both drug substance and drug product of your cytotoxic nanodrug.

Commercial manufacturing of small batches for nanodrugs

With its end-to-end services, GTP Bioways supports your project all along the development process from formulation to manufacturing and support for regulatory filing and registration.

Flexibility is at the heart of GTP Bioways’ philosophy. When most  CMOs will not take on the production of small batches, we are ideally sized to answer the need for small to medium commercial batch sizes – such as for products developed to treat orphan diseases.

Our capacities for drug products reach up to 10,000 units (syringes or vials) per batch. When larger quantities are required, we can perform a production campaign from the same bulk to meet your needs.

GTP Bioways CDMO - Bioconjugates Analytical Development

You may like ...


Analytical Development


Fill & Finish

GTP Bioways

Our facilities

White paper

A Guide to Smooth CDMO Tech Transfer

The key parameters to be considered while choosing your next CDMO, as well as our tips to assess those parameters, and more!